Pharmacogenetics: Inherited variation in amino acid sequence and altered protein quantity

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 4, 2004, Pages 253-258

  Weinshilboum, Richard ^a   Wang, Liewei ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOENZYME; ANTIHYPERTENSIVE AGENT; ARYLAMINE ACETYLTRANSFERASE; CATECHOL METHYLTRANSFERASE; CHAPERONE; CHOLINESTERASE; CYTOCHROME P450; GELDANAMYCIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HISTAMINE METHYLTRANSFERASE; HYDRALAZINE; ISONIAZID; MUSCLE RELAXANT AGENT; PROTEASOME INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFOTRANSFERASE; SUXAMETHONIUM; THIOPURINE METHYLTRANSFERASE; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUBERCULOSTATIC AGENT;

ACETYLATION; AEROBIC METABOLISM; AMINO ACID SEQUENCE; CATALYSIS; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME KINETICS; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; HUMAN CELL CULTURE; MOLECULAR CLONING; MOLECULAR MECHANICS; NONHUMAN; NOTE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN QUALITY; PROTEIN TARGETING; SINGLE NUCLEOTIDE POLYMORPHISM; UBIQUITINATION;

AMINO ACID SEQUENCE; FORECASTING; GENE FREQUENCY; HUMANS; PHARMACOGENETICS; PROTEIN CONFORMATION; PROTEINS; RESEARCH; SENSITIVITY AND SPECIFICITY; VARIATION (GENETICS);

EID: 1842687897     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.12.002     Document Type: Note

References (28)

1. Guttmacher A.E., Collins F.S. Genomic medicine - a primer. N Engl J Med. 347:2002;1512-1520.
2. Weinshilboum R. Inheritance and drug response. N Engl J Med. 348:2003;529-537.
3. Kalow W. Pharmacogenetics: past and future. Life Sci. 47:1990;1385-1397.
4. Price-Evans D.A., Manley K.A., McKusick V.A. Genetic control of isoniazid metabolism in man. BMJ. 2:1960;485-491.
5. Timbrell J.A., Harland S.J., Facchini V. Polymorphic acetylation of hydralazine. Clin Pharmacol Ther. 28:1980;250-255.
6. McGuire M.C., Nogueira C.P., Bartels C.F., Lightstone H., Hajra A., Van Der Spek A.F.L., et al. Identification of the structural mutation responsible for the dibucaine-resistent (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci U S A. 86:1989;953-957.
7. Lockridge O. Genetic variants of human butyrylcholinesterase influence the metabolism of the muscle relaxant succinylcholine. Kalow W. Pharmacogenetics of drug metabolism. International encyclopedia of pharmacology and therapeutics. 1992;15-50 Pergamon, New York.
8. Hein D.W. Molecular genetics and function of NAT1 and NAT2 role in aromatic amine metabolism and carcinogenesis. Mut Res. 506-507:2002;65-77.
9. Weinshilboum R.M., Otterness D.M., Szumlanski C.L. Methylation pharmacogenetics catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol. 39:1999;19-52.
10. Weinshilboum R.M. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos. 29:2001;601-605.
11. Preuss C.V., Wood T.C., Szumlanski C.L., Raftogianis R.B., Otterness D.M., Girard B., et al. Human histamine N-methyltransferase pharmacogenetics common genetic polymorphisms that alter activity. Mol Pharmacol. 53:1998;708-717.
12. Shield AJ, Weinshilboum RM. Human catechol O-methyltransferase (COMT) polymorphisms: functional genomic studies. Mol Psychiatr. In press 2004
13. Freimuth R.R., Eckloff B., Wieben E.D., Weinshilboum R.M. Human sulfotransferase SULT1C1 pharmacogenetics gene resequencing and functional genomic studies. Pharmacogenetics. 11:2001;747-756.
14. Thomae B.A., Eckloff B.W., Freimuth R.R., Wieben E.D., Weinshilboum R.M. Human sulfotransferase SULT2A1 pharmacogenetics genotype-to-phenotype studies. Pharmacogenomics J. 2:2002;48-56.
15. Thomae B.A., Rifki O.F., Theobald M.A., Eckloff B.W., Wieben E.D., Weinshilboum R.M. Human catecholamine sulfotransferase (SULT1A3) pharmacogenetics common functional genetic polymorphism. J Neurochem. 87:2003;809-819.
16. Adjei A.A., Thomae B.A., Prondzinski J.L., Eckloff B.W., Wieben E.D., Weinshilboum R.M. Human estrogen sulfotransferase (SULT1E1) pharmacogenetics gene resequencing and functional genomics. Br J Pharmacol. 139:2003;1373-1382.
17. Gaedigk A., Tyndale R.F., Jurima-Romet M., Sellers E.M., Grant D.M., Leeder J.S. NAD(P)H quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics. 8:1998;305-313.
18. Siegel D., McGuinness S.M., Winski S.L., Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H quinone oxidoreductase 1. Pharmacogenetics. 9:1999;113-121.
19. Brodsky J.L. Chaperoning the maturation of the cystic fibrosis transmembrane conductance regulator. Am J Physiol Lung Cell Mol Physiol. 281:2001;L39-L42.
20. Szumlanski C., Otterness D., Her C., Lee D., Brandriff B., Kelsell D., et al. Thiopurine methyltransferase pharmacogenetics human gene cloning and characterization of a common polymorphism. DNA Cell Biol. 15:1996;17-30.
21. Tai H.-L., Krynetski E.Y., Schuetz E.G., Yanishevski Y., Evans W.E. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2) mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A. 94:1997;6444-6449.
22. Tai H.-L., Fessing M.Y., Bonten E.J., Yanishevsky Y., d'Azzo A., Krynetski E.Y., et al. Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics. 9:1999;641-650.
23. Siegel D., Anwar A., Winski S.L., Kepa J.K., Zolman K.L., Ross D. Rapid polyubiquitination and proteosomal degradation of a mutant form of NAD(P)H quinone oxioreductase 1. Mol Pharmacol. 59:2001;263-268.
24. Lachman H.M., Papolos D.F., Saito T., Yu Y.-M., Szumlanski C.L., Weinshilboum R.M. Human catechol O-methyltransferase pharmacogenetics description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 6:1996;243-250.
25. Wang L., Sullivan W., Toft D., Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics chaperone protein association and allozyme degradation. Pharmacogenetics. 13:2003;555-564.
26. Wickner S., Maurizi M.R., Gottesman S. Posttranslational quality control folding, refolding and degrading proteins. Science. 286:1999;1888-1893.
27. Höhfeld J., Cyr D.M., Patterson C. From the cradle to the grave molecular chaperones that may choose between folding and degradation. EMBO Rep. 21:2001;885-890.
28. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med. 8:2002;S55-61.